Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
somatropine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| somatropine | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| somatropine | DRUG | subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg |
Inclusion Criteria: * Children over 3 years of age with growth hormone deficiency, requiring treatment with MAXOMAT® according to the criteria of the MA. Exclusion Criteria: * The above information is not intended to contain all considerations relevant to a patient's potential participation in a ...
Somatropine is used for growth hormone deficiency. It is being developed by Sanofi as a small molecule for the endocrine condition. The drug is currently in Phase 3 clinical development, though it remains investigational and is not yet approved.
Sanofi (ticker: SNY) is developing somatropine. The company is conducting clinical trials for the drug, which is intended to treat growth hormone deficiency. Somatropine is in Phase 3 development.
Somatropine is in Phase 3 clinical development. It is an investigational drug for growth hormone deficiency and has not been approved. One Phase 3 trial has been completed, involving 12 participants.
Somatropine has one completed Phase 3 trial, NCT00476385, titled 'Practicability and Acceptability of Stylomax® in Children'. The study enrolled 12 participants with growth hormone deficiency in France, with a minimum age of 3 years. It was an uncontrolled, non-randomized trial.
Yes, somatropine is associated with the brand name Stylomax, as indicated by the clinical trial title 'Practicability and Acceptability of Stylomax® in Children'. The trial evaluates somatropine for growth hormone deficiency.